Medincell SA - Asset Resilience Ratio

Latest as of March 2026: 20.39%

Medincell SA (MEDCL) has an Asset Resilience Ratio of 20.39% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Medincell SA (MEDCL) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€22.03 Million

≈ $25.76 Million USD Cash + Short-term Investments

Total Assets

€108.05 Million

≈ $126.33 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2026)

This chart shows how Medincell SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Medincell SA (MEDCL) total assets.

Liquid Assets Composition Over Time

This chart breaks down Medincell SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Medincell SA long-term investment intensity to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€22.03 Million	20.39%
Total Liquid Assets	€22.03 Million	20.39%

Asset Resilience Insights

Good Liquidity Position: Medincell SA maintains a healthy 20.39% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Medincell SA Industry Peers by Asset Resilience Ratio

Compare Medincell SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Medincell SA (2016–2026)

The table below shows the annual Asset Resilience Ratio data for Medincell SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2026-03-31	20.39%	€22.03 Million ≈ $25.76 Million	€108.05 Million ≈ $126.33 Million	-39.09pp
2025-03-31	59.48%	€53.80 Million ≈ $62.90 Million	€90.45 Million ≈ $105.75 Million	+31.55pp
2024-03-31	27.93%	€10.32 Million ≈ $12.06 Million	€36.95 Million ≈ $43.20 Million	+27.92pp
2023-03-31	0.01%	€3.00K ≈ $3.51K	€29.34 Million ≈ $34.30 Million	-15.72pp
2022-03-31	15.73%	€6.97 Million ≈ $8.15 Million	€44.30 Million ≈ $51.79 Million	+6.65pp
2021-03-31	9.08%	€5.78 Million ≈ $6.75 Million	€63.61 Million ≈ $74.36 Million	-6.81pp
2020-03-31	15.89%	€4.34 Million ≈ $5.07 Million	€27.31 Million ≈ $31.92 Million	-24.90pp
2019-03-31	40.80%	€15.49 Million ≈ $18.12 Million	€37.98 Million ≈ $44.40 Million	+40.66pp
2018-03-31	0.14%	€35.00K ≈ $40.92K	€25.35 Million ≈ $29.64 Million	-19.26pp
2017-03-31	19.40%	€4.51 Million ≈ $5.28 Million	€23.27 Million ≈ $27.20 Million	+2.62pp
2016-03-31	16.78%	€1.88 Million ≈ $2.19 Million	€11.17 Million ≈ $13.06 Million	--

pp = percentage points

About Medincell SA

PA:MEDCL France Biotechnology

Market Cap

$898.42 Million

€768.47 Million EUR

Market Cap Rank

#9958 Global

#155 in France

Share Price

€21.40

Change (1 day)

-1.74%

52-Week Range

€20.24 - €38.46

All Time High

€38.46